Home

P63 squamous cell carcinoma lung

P63 expression in lung carcinoma: a tissue microarray

In histology and cell block sections, antibodies to thyroid transcription factor-1 (TTF-1) and p63 have been demonstrated to be useful markers for distinguishing between small-cell lung carcinoma.. In both studies, p63 immunoreactivity was described as rare, focal or multifocal, sharply contrasting with larger, positively stained areas of squamous cell carcinoma. The mean percentage of..

Value of P63 and CK5/6 in distinguishing squamous cell

  1. Solid cell nests. p63+ in many follicles. Correlates with a loss of TTF1. Adenoid cystic carcinoma, solid. Seromucinous hamartoma p63-, no myoepithelial cells, positive internal control. Nephrogenic adenoma (p63-/AMACR+) Adenocarcinoma (upper, p63-/AMACR+) and benign (lower, p63+/AMACR-
  2. squamous cell carcinoma (SCC), and malignant mesothelioma (MM) in effusion can be a diagnostic challenge based on mor-phology alone. This study evaluates the utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immu-nostains in effusions when ADC and SCC of the lung are in the differential diagnosis with MM
  3. Bishop et al showed that in 81 cases of squamous cell carcinoma of the lung and 237 cases of adenocarcinoma of the lung, the sensitivity and specificity of p63 were 100.00 and 69.20%, respectively. The sensitivity and specificity of p40 in the diagnosis of squamous cell carcinoma of the lung were 100 and 98%, respectively
  4. Squamous cell lung carcinoma is a type of non-small cell lung cancer (NSCLC). According to the American Cancer Society, about 80 to 85 percent of all lung cancers are non-small cell.. Squamous.
  5. While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between adenocarcinomas (ACs) and SCCs is P63
  6. Squamous carcinoma or squamous cell carcinoma is the name of a type of non-small cell lung cancer where the cells resemble the flat cells Adenocarcinoma is a type of non-small cell lung cancer where the cells resemble gland cells, such as the glands that secrete mucus in the lungs. p63, p40, cytokeratin 5/6, TTF-1, and napsin A are.
  7. Maspin, p63 and p53 were expressed in squamous cell carcinoma of the lung with the majority of cases exhibiting strong and diffuse positivity. The frequencies of their staining were 83/86 (96.5%) for maspin, 79/86 (91.9%) for p63, and 77/86 (89.5%) for p53

The p63 genomic sequence was amplified in 88% of squamous carcinomas, in 42% of large cell carcinomas, and in 11% of adenocarcinomas of the lung. The predominant splice variant of p63 expressed was ΔNp63α. Western analyses revealed ΔNp63α expression in normal bronchus and squamous carcinomas but not in normal lung or in adenocarcinomas TTF-1, CK7 and p63 expression have been used to differentiate primary lung cancers; however, the need for a sensitive and specific panel of antibodies to differentiate lung adenocarcinoma from lung SqCC is of the utmost importance. Thrombomodulin (CD141), p63, 34betaE12 and CK5/6 have been shown to be sensitive markers for SqCC

P63 differentiates subtypes of nonsmall cell carcinomas of

Pathology Outlines - p63

The specificity of CK5 for squamous cell carcinoma was higher than p63. Abstract Utility of TTF-1, NapsinA, Ck5 and p63 in distinguishing between Adenocacinoma and Squamous cell carcinoma, using fine needle aspiration cellblock material and paraffin embedded biopsy specimens in a resource limited setting nuclear staining. Positive. squamous cell carcinoma, urothelial carcinoma. Negative. prostate carcinoma, most lung adenocarcinoma, breast carcinoma. p63 is a commonly used immunostain. p63, like most other p stains, is a nuclear stain Histological subtyping of non-small cell lung cancer (NSCLC) is of utmost importance for therapy stratification. Common immunohistochemical markers to identify squamous lineage are CK5/6, p40, and p63. Although p40 is considered the gold standard by current guidelines, the agreement of all three markers is an important aspect for tumours more.

p63 In pulmonary epithelium, pulmonary squamous neoplasms

A comprehensive study has shown that TRIM29 is a sensitive marker (93.7%) for lung squamous cell carcinoma (SqCC) and is a fairly specific marker staining only 6.1% of lung adenocarcinomas. p63 is a nuclear stain that marks lung SqCC (DAB), and TRIM29 is a cytoplasmic/membrane stain that also marks lung SqCC (Fast Red) SOX2/P63 pathway is an essential regulator of corneal stem/progenitor cells while mutations in SOX2 or P63 may disrupt epithelial regeneration, leading to loss of corneal transparency and blindness. TP63 directly regulates NRG1 expression in human squamous cell carcinoma cell lines Mediastinal large B cell lymphoma; Metastatic Carcinoma must be ruled out before the diagnosis of primary thymic carcinoma is made. Clinical findings, history and imaging are most valuable; CD5 and/or CD117 positivity are suggestive of thymic primary but not specific 15-20% of lung squamous carcinomas are positive for these marker

Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). It is the second most prevalent type of lung cancer after lung adenocarcinoma and it originates in the bronchi.Its tumor cells are characterized by a squamous appearance, similar to the one observed in epidermal cells.Squamous-cell carcinoma of the lung is strongly associated with tobacco. The p63 genomic sequence was amplified in 88% of squamous cell carcinomas, in 42% of large cell carcinomas, and in 11% of adenocarcinomas of the lung. The predominant splice variant of p63 expressed was DNp63a. Western blot analyses revealed DNp63a expression in the normal bronchus and squamous carcinomas, but not in the normal lung or in. A, Kaplan-Meier survival curve shows significant prolonged survival associated with patients with tumors exhibiting genomic amplification of p63 [p63 ≥ 3, n = 73; p63 CN <3 (n = 6)] in squamous carcinoma of the lung, P < 0.05. B, effect of p63 immunostaining intensity on odds of surviving from squamous carcinoma of the lung. Scores of 1-4. KEY WORDS: bevacizumab, nonsmall cell carcinoma, p63, squamous differentiation. In the United States, lung cancer is the leading cause of cancer-related death in both men and women.1 Approxi-mately 85% are nonsmall cell carcinoma (NSCC). Tradi-tionally, the distinction between small cell carcinoma an Squamous cell carcinomas of different organs, including head and neck, cervix, and lung, as well as basal cell carcinomas of the skin showed strong nuclear p63 expression. A similar pattern of immunostaining has been reported by several groups (4 , 9 , 19)

The sensitivity and specificity of CK5/6, P63 in squamous cell carcinoma of lung cancer is 77.05 % and 96.44 %, 83.61 % and 88.93 % respectively, which has statistical significance compared to adenocarcinoma of lungs and small cell lung carcinoma (P<0.01). The positive rate of P40 in squamous cell carcinoma of lungs is 100 % nad tit Squamous metaplasia (SM) is an irreversible form of airway epithelial remodeling. Hyperproliferation of basal cells was observed in squamous metaplastic epithelium of chronically inflamed airway. However, the association of such aberrant proliferation of basal cells with SM in the nasal epithelium after radiation damage remains unclear. The aim of this study was to investigate SM and. Cytokeratin 14 should be positive in squamous cell carcinoma, but my personal experience is that in poorly differentiated squamous cell carcinoma it is often negative. p63 and TTF-1 both have the advantage of being nuclear stains, avoiding the problem of scant cytoplasm in small cell carcinoma and in the small cell variant of squamous cell. If a tumor stains positive for both TTF-1 and p63, it is more likely to be an adenocarcinoma than a squamous cell carcinoma because TTF-1 is a more sensitive marker than p63. Cytokeratin (CK) 5 positivity can be seen in undifferentiated large cell carcinoma as well as squamous carcinoma of the lung

However, other reports have found that p63-positive cases had a worse prognosis in patients with oral squamous cell carcinoma , adenoid cystic carcinoma of the salivary gland , and Merkel cell carcinoma . There are scant data on the association between p63 expression and the prognosis of MEC Introduction. Lung cancer is the leading cause of cancer death both in men and women worldwide .NSCLC accounts for about 80-85% of all lung cancers and is classified according to the World Health Organization criteria into three major types: adenocarcinoma (50%), squamous cell carcinoma (30-35%), and large cell carcinoma (5-10%) . Prior to lung cancer patient treatment, it is important. Identification of squamous differentiation in poorly differentiatied carcinoma from various sites, particularly when coexpressed with CK5/6 5. Coexpression of p63 and CK5/6 had a sensitivity of 0.77 and a specificity of 0.96 for squamous cell carcinomas

Suggested immunostains used in the differentiation of basaloid squamous cell carcinoma from small cell lung carcinoma/large cell neuroendocrine carcinoma. Immunostain Basaloid SqCa SCC/LCNEC; Immunostain-p63 + −: 34βE12 + −: TTF-1: − + Neuroendocrine markers (synaptophysin, chromogranin, CD56) − Here we compared the standard p63 antibody (4A4) and p40 in a series of 470 tumors from the archives of Memorial Sloan-Kettering Cancer Center and The Johns Hopkins Hospital, which included lung squamous cell carcinomas (n=81), adenocarcinomas (n=237), and large cell lymphomas (n=152)

Lung Tumors Prepared by Kurt Schaberg Adenocarcinoma Malignant epithelial tumor with glandular differentiation, mucin production, or pneumocyte marker expression. Lung Cancer (including other carcinoma types) is the most common cause of cancer death world-wide. Strong association with tobacco smoking.Other risk factors: Radon, air pollution, occupational exposur We demonstrate that ΔNp63α is an essential survival factor in head and neck squamous cell carcinoma (HNSCC) through its ability to suppress p73-dependent apoptosis. Inhibition of endogenous p63 expression by RNAi induces apoptosis selectively in HNSCC cells that overexpress ΔNp63α. Knockdown of p63 induces the proapoptotic bcl-2 family members Puma and Noxa, and both their induction and. The most cost-effective tissue-preserving panel for small biopsy specimens in the differential diagnosis of lung adenocarcinoma versus squamous cell carcinoma is a combination of p63 and napsin A. Lung cancer is the leading cause of cancer-related mortality, both in the United States and worldwide. 1 - 5 Lung cancer is the second most-common.

Non-small Cell Carcinoma of the Lung, FNA | These cells

Project description:Lung squamous cell carcinoma (SCC) is a deadly disease for which current treatments are inadequate. We demonstrate that biallelic inactivation of Lkb1 and Pten in the mouse lung leads to SCC that recapitulates the histology, gene expression, and microenvironment found in human disease Saladi et al. show that ACTL6A, which encodes an SWI/SNF subunit, is frequently amplified and highly expressed together with TP63 in head and neck squamous cell carcinoma (HNSCC). ACTL6A and p63 coordinately regulate key genes, including WWC1, to dictate oncogenic YAP activity and patient outcomes in HNSCC Although NRG1 has already been established as a TP63 target in breast cells and NRG1/ERBB signaling has already been reported to play a role in squamous cell carcinoma biology, a strength of the work is the use of human material, murine models and cancer cell lines as well as an antibody to block NRG, which suggests that blocking NRG may affect. diagnosed bronchial squamous cell lung carcinoma after severe bronchitis: A case report Yoonjoo Kim1*, Geon Yoo2*, Da-Hye Lee1, Choong-Sik Lee3 and Chaeuk Chung1 Abstract Spontaneous regression of lung cancer is exceptionally rare. But there have been several intriguing cases reported in early and even advanced stages of lung cancer p63 expression is not uncommonly seen in adenocarcinomas, whereas ΔNp63 (p40) expression is specific for squamous cell carcinoma, with sensitivity comparable to that of p63 expression. Presence of p63-positive cells in poorly differentiated lung adenocarcinoma may be erroneously interpreted as evidence of squamous cell differentiation

TTF-1 and p63 for distinguishing pulmonary small-cell

Previous studies have reported that p63 and p53 control maspin expression by transactivating the promoter. The present study analyzed immunohistochemical studies to determine the expression and coexpression patterns of maspin, p63 and p53 in non-small cell lung carcinoma, specifically squamous cell carcinoma and adenocarcinoma Squamous cell carcinoma of the lung, also lung squamous cell carcinoma, is a common malignant lung tumour that is associated with smoking.. It is also known as squamous carcinoma of the lung and lung squamous carcinoma.. Squamous cell carcinoma can be abbreviated SCC; however, this can be confusing as small cell carcinoma is sometimes abbreviated as such

p63 expression in assessment of bronchioloalveolar

Recent molecular biological studies have identified podoplanin as a candidate cancer stem cell (CSC) marker in squamous cell carcinoma (SqCC). The purpose of this study was to examine the expression pattern of podoplanin, and the other stem cell markers CD44 and p63, and their relationship to clinico-pathological features including survival in pulmonary SqCC Histologic transformation of lung cancer is also involved in a series of signaling pathways 12. Lung adenocarcinoma to squamous cell carcinoma transformation is correlated to the PI3K/AKT/mTOR pathway, in addition to the initial EGFR mutation, genomic alterations in PTEN, LKB1, PIK3CA 13 CONCLUSIONS: The authors concluded that p63 is a use- ful marker for the detection of nonsmall cell carcinomas of lung with squamous differentiation when used in cytologic pulmonary samples. p63 immunocytochemistry significantly increases the sensitivity for the identification of lung neoplasms with squamous differentiation from 35% to 88% (P.

Pathology Outlines - p6

P40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma Justin A. Bishop , Julie Teruya-Feldstein, William H. Westra, Giuseppe Pelosi, William D. Travis, Natasha Rekhtma Mutations in squamous cell carcinoma of lung 1 Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations Running title: Mutations in squamous cell carcinoma of lung Key words: EGFR, KRAS, TTF-1, p63, squamous cell carcinoma Natasha Rekhtman1, Paul K. Paik2, Maria E. Arcila1, Laura J. Tafe1,3. Lung cancer, primarily associated with tobacco use, is the leading cause of cancer morbidity and mortality in the United States. Squamous cell carcinoma (SCC) is one of the four major histological types of lung cancer. Although there are several established models for lung adenoma and adenocarcinomas, there is no well-established mouse model for lung SCC

Immunohistochemistry has recently emerged as a powerful ancillary tool for differentiating lung adenocarcinoma and squamous cell carcinoma-a distinction with important therapeutic implications. Although the most frequently recommended squamous marker p63 is extremely sensitive, it suffers from low. Monoclonal p63 (4A4) antibody is conventionally used to mark lung squamous cell carcinoma. However, it also weakly stains the nuclei of up to 30% of lung adenocarcinomas. Another antibody, p40, recognizes ΔNp63, which is a p63 isoform

Here we compared the standard p63 antibody (4A4) and p40 in a series of 470 tumors from the archives of Memorial Sloan-Kettering Cancer Center and The Johns Hopkins Hospital, which included lung squamous cell carcinomas (n=81), adenocarcinomas (n=237), and large cell lymphomas (n=152). The p63 was positive in 100% of squamous cell carcinomas. INTRODUCTION. Major therapeutic advancements in lung cancer based on molecular testing have been observed over the last decade. Prior to the 2000s, lung cancer was classified into the following two major groups that received distinct treatments: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) including squamous cell carcinoma (SQCC), adenocarcinoma (ADC), large cell. carcinoma (50-70%), squamous cell carcinoma (20-30%) and other subtypes (<10%) [3,4]. Molecular studies of lung cancers have led to the development of personal-ized/targeted therapy [5-12]. An important example is the discovery of epidermal growth factor receptor gene (EGFR) alterations, and the successful administration of EGFR tyrosine kinase. Large cell carcinoma (LCC) accounts for about 3-9 % of all primary pulmonary malignancies. It has been historically considered as one of the three main histological types among the broad category of non-small cell lung cancer (NSCLC), along with adenocarcinoma (ADC) and squamous cell carcinoma (SQC) [1, 2].According to the 2004 World Health Organization (WHO) classification of lung tumors. Lung cancer metastasis is typically determined by histologic similarity between distant and primary lesions. Herein, we present a 70-year-old Japanese woman with an adenocarcinoma in her lung and a squamous cell carcinoma in her femur; both tumors had an identical epidermal growth factor receptor mutation, G719S

Non-small cell cancer accounts for 85% to 90% of all lung cancers (1). According to GLOBOCAN, lung cancer has been the most common cancer globally for several decades (2). GLOBOCAN estimated worldwide incidence of lung cancer in 2012 to be 1,824,701 (12.9% of all cancers) with an ASR of 23.1 per 100,000 Found to be as or more sensitive than p63 4,5,6; Studies indicate p40 has higher specificity in squamous cell carcinoma than p63 4,5,6; May offer a suitable replacement for p63 in various tumour types 7,8; Can be used in a stratification panel with other key markers 9,1 Collectively, these results reveal an unanticipated role for p63-driven paracrine FGFR2 signaling as an addicting pathway in human cancer and suggest a new approach for the treatment of SCC. Introduction Squamous cell carcinoma (SCC) is a treatment-refractory malig-nancy arising within the epithelium of the skin, lung, esopha

E, squamous carcinoma with strong staining for the majority of the tumor cells yet decreasing in most differentiated area. F, adenocarcinoma with no staining for p63. Fig. 5 .5p63 gene CN and expression in preinvasive lung cancer. A, p63/FHIT gene CN ratio by FISH during tumorigenesis Lung squamous cell carcinoma (LSCC) remains a challenging disease to treat, and further improvements in prognosis are dependent upon the identification of LSCC-specific therapeutic biomarkers and/or targets. We previously found that Syntaxin Binding Protein 4 (STXBP4) plays a crucial role in lesion growth and, therefore, clinical outcomes in LSCC patients through regulation of tumor protein. Either metastatic or primary squamous cell carcinoma in the gastrointestinal tract is extremely rare, with very few cases reported in the literature. In this paper, we report a case in which the patient presented with dysphagia during the course of radiotherapy for recurrent lung cancer in a mediastinal lymph node. Although the dysphagia mimicked radiation esophagitis, the ultimate cause.

Lung cancer is the second most common cause of cancer deaths in the U.S. Lung cancers exist as three subtypes: non-small cell lung cancers (NSCLC), which are comprised of the adenocarcinoma and squamous cell carcinoma subtypes that together account for 75% of cases, and small cell lung cancers (neuroendocrine origin) which account for the. Both P63 and CK5/6 expression was seen in 9/12 (75%) SQCC cases; none of the ADC cases showed this dual expression. Cytomorphology alone may not be able to stratify all cases of nonsmall cell lung carcinoma into ADC and SQCC in FNA specimens. The immune-panel of TTF-1, CK7, CK20, P63, and CK5/6 is useful in differentiating SQCC from ADC In histology and cell block sections, antibodies to thyroid transcription factor-1 (TTF-1) and p63 have been demonstrated to be useful markers for distinguishing between small-cell lung carcinoma and poorly differentiated pulmonary squamous cell carcinoma Sep. 18, 2018 — Researchers sheds light on p63 activity in squamous cell carcinoma of the lung, providing an actionable path forward to drug development against this known cause of.

A combination of cytokeratin 5/6, p63, p40 and MUC5AC are

cell lung carcinomas. Cytoplasmic localization of p63, only rarely described, is also associated with poor patient survival. Keywords: giant cell carcinoma, aberrant p63, lung carcinoma. I. C. ase . P. resentation 59 year-old non-smoking female presented to the Emergency Department with worsening fever of one day duration reaching up to 102˚ diagnosis of squamous carcinoma [8]. p63 and CK5/6 are traditional markers that indicate squamous differen-tiation [9]. In primary lung neoplasms, most squamous carcinomas and large cell carcinomas are positive for CK5/6 [10]. Warth et al found that the probability of a correct SQCC diagnosis using CK5/6 is 86.9% [11]. p63, a transcriptional. Squamous cell carcinoma is confirming with p40 antibody which is also known as DNp63. p40 is expressed in the nucleus of malignant cells of squamous cell carcinoma . This antibody is more specific for squamous cell lung carcinoma from p63. p40 is expressed in a smaller number of lung adenocarcinoma cells than p63 The p63 gene is often overexpressed in squamous cell carcinomas; however, how its overexpression contributes to tumor formation and expansion is still incompletely understood. Devos et al. report the development of a versatile mouse model demonstrating that p63 facilitates squamous cell carcinoma for-mation in skin and providing an excellent.

Wu M, Wang B, Gil J, Sabo E, Miller L, Gan L, et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol. 2003;119:696-702. Article PubMed Google Scholar 29 Lung cancer is the most common cause of cancer-related death worldwide and lung squamous cell carcinomas (SCC) account for 20-30% of all NSCLC p63 is a member of the p53 protein family and plays a crucial role in epithelial development. p63 is expressed in many types of tumors including esophageal cancer; however, its function in cancer is controversial and its role in esophageal cancer has not been clearly established. In the present study, we aimed to identify the mechanisms by which p63 promotes proliferation of esophageal.

Squamous Cell Lung Carcinoma: Treatment, Staging, and Mor

Squamous cell carcinoma (SCC) is a treatment‐refractory tumour which arises from the epithelium of diverse anatomical sites such as oesophagus, head and neck, lung and skin.Accumulating evidence has revealed a number of genomic, clinical and molecular features commonly observed in SCC of distinct origins. Some of these genetic events culminate in fostering the activity of ΔNp63, a potent. Found to be as or more sensitive than p63,3,4,5; Studies indicate p40 has higher specificity in squamous cell carcinoma than p63 3,4,5; May offer a suitable replacement for p63 in various tumor types 6,7; Can be used in a stratification panel with other key markers 8, In some cases, the cancer does not microscopically resemble squamous cell carcinoma, adenocarcinoma, small cell carcinoma, or any of the other more rare variants of lung cancer. These cancers are undifferentiated large cell carcinoma or non-small cell carcinoma. The prognosis of these tumors is better than small cell carcinoma and i About 10 to 15 percent are small cell lung cancer (SCLC). These two types of lung cancer are treated differently. While survival rates vary, stage 3 lung cancer is treatable. Many factors affect. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC.

Figure 2 | Difference of Morphology and Immunophenotype

Cancer Science 2009 Vol. 100; Iss. 11 Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung Yoshihisa Shimada , Genichiro Ishii , Kanji Nagai , Naho Atsumi , Satoshi Fujii , Atsushi Yamada , Yuki Yamane , Tomoyuki Hishida , Mitsuyo Nishimura , Junji Yoshida , Norihiko Ikeda , Atsushi Ochia Lung cancer is one of the largest causes of cancer death in Japan and other countries including the USA. Squamous cell carcinoma (SqCC) occupies approximately 30% in all lung cancers . It can be classified into the central type squamous cell caranoma (cSqCC) and the peripheral type squamous cell caranoma (pSqCC) according to the location of the.

Expression of Ki67 and P53 in primary squamous cellpulmonary-respiratory-cytological-diagnosisSurgically resected gastric metastasis of pulmonaryPrimary small cell neuroendocrine carcinoma of the

Key Words: napsin-A; TTF-1; p63; cytology; lung cancer Lung cancer is one of the most frequently diagnosed malignancies and is the most common cause of cancer mortality in the world.1,2 Adenocarcinoma (ADC) has become the most common subtype of lung carcinoma and can be distinguished from other subtypes of nonsmall cell lung carcinoma (NSCLC. Squamous cell carcinoma (SCC) is a highly malignant cancer which arises from the squamous epithelium of oesophagus, head and neck, lung and skin. The inci-dence of SCC varies between different types ranging from 600 000 cases per year for head and neck SCC (HNSCC) to 450 000 cases for lung SCC (Ferlay et al., 2015). Although derived from distinc Squamous cell carcinoma (SCC) is a highly malignant cancer which arises from the squamous epithelium of oesophagus, head and neck, lung and skin. The incidence of SCC varies between different types ranging from 600 000 cases per year for head and neck SCC (HNSCC) to 450 000 cases for lung SCC (Ferlay et al ., 2015 )